6 results about "Post radiotherapy" patented technology

This invention discloses an artificial intelligence-based intervention system for tumor radiotherapy rehabilitation nursing, belonging to the field of tumor rehabilitation nursing technology. By integrating multi-dimensional data and combining clinical standard output quantitative assessment levels and key weakness dimensions, this invention accurately identifies patients' rehabilitation shortcomings, providing targeted objectives for the nursing intervention strategy generation module and generating personalized plans to ensure the intervention's relevance and feasibility. It captures strategy execution data in real time and dynamically adjusts the plan, ensuring the intervention process always adapts to changes in the patient's rehabilitation status. Simultaneously, by regularly collecting core indicators and linking risk escalation and priority intervention, it strengthens proactive management of high-risk groups, realizing a shift from passive response to proactive prediction in tumor radiotherapy rehabilitation nursing, thus optimizing the overall quality of post-radiotherapy rehabilitation nursing and patient prognosis.

This invention relates to the field of biomedical technology, disclosing a drug combination and its application for improving the sensitivity of FLASH radiotherapy in the treatment of colorectal cancer peritoneal metastases. The combination comprises a therapeutically effective amount of an APOE inhibitor and / or an IL1B agonist. By combining an APOE inhibitor and / or an IL1B agonist, this invention can precisely target and intervene in abnormal gene expression after FLASH radiotherapy, thereby improving the abnormal gene expression state after FLASH radiotherapy, eliminating the negative impact of abnormal gene expression on the efficacy of radiotherapy, significantly improving the therapeutic sensitivity of FLASH radiotherapy to colorectal cancer peritoneal metastases, achieving radiosensitization, and providing a new targeted strategy for the radiotherapy treatment of colorectal cancer peritoneal metastases.

This invention discloses a method for radiotherapy target localization based on biodegradable radiopaque ceramic markers. The method involves customizing and standardizing biodegradable radiopaque ceramic markers to match the radiotherapy cycle, based on pre-defined tumor lesion parameters and full-cycle radiotherapy parameters. Target area image data of the implanted non-coplanar markers are acquired, and coordinate system registration, precise target delineation, and radiotherapy planning parameters are determined based on CT thin-slice images. Before radiotherapy, the markers are used to verify their position, and positioning correction parameters are output for radiotherapy equipment calibration. After radiotherapy, the degradation of the markers is monitored based on follow-up images. This invention achieves precise radiotherapy target localization, uses markers without artifact imaging, has a degradation cycle precisely matched to the radiotherapy cycle, is completely degradable without the need for secondary surgery, and exhibits excellent biocompatibility.

This invention relates to the field of damage assessment technology, specifically to an intelligent assessment method and system for the degree of tumor tissue damage after radiotherapy. The method includes the following steps: based on the radiation dose distribution and voxel grayscale information output by the radiotherapy equipment, temporal pairing and spatial indexing are completed; then, grayscale changes are analyzed to determine the tumor boundary; grayscale and dose characteristics are statistically analyzed layer by layer; spatial localization items of sensitive layers are identified; damage grading parameters are adjusted; and damage grading classification markers are output. This invention dynamically registers the spatial structure of radiation dose with voxel grayscale data to establish a multi-ring layer parameter set for the tumor and adjacent tissues, achieving layered localization and extracting key spatial features. It directly correlates dose distribution differences with damage grading adjustment parameters. Combined with spatial markers and grading standards, it can accurately classify the radiation response of the tumor boundary and adjacent sensitive areas, completing a detailed determination of the damage level and improving the structured expression and multi-dimensional identification capabilities of the assessment results.

This invention relates to the application of DTX3 or reagents that promote DTX3 expression in the preparation of products reversing radioresistance in nasopharyngeal carcinoma (NPC), belonging to the field of biomedical technology. The invention found that, compared to parental NPC cells, Deltex E3 ubiquitin ligase 3 (DTX3) expression is significantly reduced in radioresistant NPC. Overexpression of DTX3 can reverse radioresistance in NPC cells and inhibit homologous recombination repair after radiotherapy in NPC, thus allowing DTX3 to be used to reverse radioresistance in NPC. This invention provides a new biomarker for the diagnosis of radiotherapy response in NPC, an effective method for reversing radioresistance in NPC, and a new treatment option for NPC.

The application discloses a radiation-proof and oxidation-resistant coating, a helmet probiotic and a preparation method and application thereof, and relates to the technical field of probiotics, and specifically discloses a radiation-proof and oxidation-resistant coating which comprises a plurality of bismuth oxide particles, the surface of the bismuth oxide particles is coated with a metal polyphenol network layer formed by the reaction of polyphenols and trivalent cerium ions, and the metal polyphenol network layer is used for connecting the coated bismuth oxide particles to intestinal probiotics. The helmet probiotic of the application can be long-acting and fixed in the intestinal tract and carries a coating with radiation-proof and oxidation-resistant functions, can effectively prevent the damage to the intestinal tract during radiotherapy, can significantly reduce the oxidative stress reaction after radiotherapy, can reduce the inflammatory reaction, can protect the intestinal tissue, and can improve the survival level of tumor patients after recovery.